InvestorsHub Logo
Followers 87
Posts 6773
Boards Moderated 1
Alias Born 09/18/2009

Re: eb0783 post# 40346

Friday, 08/18/2023 7:19:29 AM

Friday, August 18, 2023 7:19:29 AM

Post# of 43161
I can't see a situation in which you would ever have to apologize to me for anything, even though I try to express myself more precisely in some instances, because of your counsel, but fail on times to do so.

I yield and agree to your point that lenz doesn't prevent or treat covid infection. I have been saying "covid pneumonia" every time I can remember to do so, and that is always in deference to your guidance.

So, I would like to see the reinfection rate of covid pneumonia in lenz treated patients.

Forgive me in advance if I forget to add "pneumonia" in discussing this. But it's going to be harder to do so in the future, because lenz is being touted as part of a cure in CMML cancer, because that cancer is myeloid-driven, and, although lenz doesn't treat that cancer, it prevents it by blocking the virus from attaching to GM-CSF.

Restoring the body's immune response is an element of discussion I have seen in regards to the use of lenz. I think keeping the integrity of our immune response is critical, as these manufactured covid variants have the intention of changing our bodies' natural responses. I think we'll learn more about this as we continue to develop our lenz/vaccine/anti-viral cocktail, as well as we incorporate TeraImmune's TReg development.

Besides all else, I want to have, and express, the fullest appreciation of lenzilumab's potential. Management is not positioned to speculate. They can only state facts that are proven, in my opinion. So there's no way anything I say is going to be 100% accurate. And I'm glad to see that you recognize that.

Always, always, appreciate hearing from you, eb.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.